Argobio Studio has announced the successful seed financing of Enodia Therapeutics, a biotechnology company developing small-molecule therapies for targeted protein degradation. The company raised €20.7 million (US$25 million) in a round co-led by Elaia, Pfizer Ventures and Bpifrance, with participation from Wallonie Entreprendre, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.

Enodia was founded by Argobio Studio following identification of foundational research from a leading researcher at the Pasteur Institute. The company’s proprietary discovery platform uses machine learning and proteomics to selectively modulate the SEC61 translocon, where secreted and transmembrane proteins are directed into the secretory pathway at the point of synthesis. This approach aims to intervene upstream of disease processes without compromising vital physiological functions.

The platform integrates machine-learning-driven selectivity, proteomics-based secretome analysis and structural validation to guide rational drug design. By doing so, Enodia seeks to unlock previously undruggable secreted and membrane protein targets for high-unmet-need conditions.

“Enodia is the third of eight companies created by Argobio to achieve seed financing, underscoring the strength and consistency of our studio model,” said Daniel Sobral, chief financial officer and head of corporate development at Argobio. “Our operational venture-building approach is designed to rapidly translate Europe’s leading scientific innovation into globally competitive biotech companies. Enodia is a strong example of this model, based on exceptional foundational research from Institut Pasteur and built by Argobio. We are proud to have brought together a high-quality syndicate of leading international investors to support the company through its next stage of development.”

Yves Ribeill, chief executive officer of Enodia Therapeutics, said: “We are grateful for the strong support and confidence of our investor syndicate, and in particular for Argobio’s long-term commitment and company-building approach. Working closely with the Argobio team from the outset enabled us to shape Enodia’s strategy and more rapidly assemble our industrial capabilities while also advancing our highly differentiated small-molecule approach to selectively modulating the SEC61 translocon. With this financing, we are well positioned to progress our lead program to preclinical candidate selection over the coming year, representing an important value inflection point for Enodia.”

Enodia is the third Argobio-founded company to achieve seed financing in 2025, following Elkedonia, which raised €11.25 million in June for non-hallucinogenic neuroplasticity enhancers targeting treatment-resistant depression, and Laigo Bio, which secured €11.5 million in December to advance its precision membrane protein degradation platform.